News
Videos
Conferences
Events
Resources
Subscribe

News|Videos|October 25, 2017

Understanding Targeted Therapies

Newsletter

Stay up to date on cancer updates, research and education

Related Content

Image of Kim.

Grieving After Cancer: Advice for Those Grieving and Supporting Them

January 28th 2026

A phase 2 trial showed onvansertib plus FOLFIRI and Avastin improved response and disease control in first-line RAS-mutated metastatic colorectal cancer: © stock.adobe.com.

Onvansertib Combo Improves Outcomes in First-Line RAS-Mutated mCRC

January 28th 2026

FDA

FDA Grants Orphan Drug Status to CTD402 for Rare T-Cell Blood Cancers

January 28th 2026

The NCCN Clinical Practice Guidelines in Oncology now include Besremi as a Category 1 preferred treatment option for some with high-risk essential thrombocythemia: © stock.adobe.com.

Besremi Recognized by Updated Guidelines for Essential Thrombocythemia

January 28th 2026

Dr. Anne Peled

Breast Cancer Surgeon and Survivor Undergoes Nerve-Sparing Procedure

January 27th 2026

Trending on CURE

FDA Approves Darzalex Faspro-VRd For Newly Diagnosed, Transplant Ineligible Multiple Myeloma

Beyond Statistics: Lessons in Mindset and Action from a Cancer Survivor

Cancer and Answering the Phone

FDA Fast Tracks IBI3003 For Relapsed/Refractory Myeloma

FDA Grants Designation to Bezuclastinib Combo in Advanced GIST